Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
2024年5月21日 - 9:17PM
ビジネスワイヤ(英語)
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL
Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta
presentation from a late-breaker poster to an oral presentation.
The SOLSTICE data will be presented on June 8 during the annual
meeting of the European Association for the Study of the Liver,
EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The
Company plans to host an investor conference call to discuss the
new SOLSTICE data on June 5. The update will include data on
participants that have reached 12 and 24 weeks of chronic
suppressive treatment. The Company will also share 48-week
treatment data on the efficacy and safety of tobevibart and
elebsiran for the participants that were previously reported on at
the 2023 American Association for the Study of Liver Diseases
(AASLD) The Liver Meeting®.
The SOLSTICE trial (NCT05461170) is evaluating the safety,
tolerability and efficacy of tobevibart and elebsiran for the
treatment of people living with chronic hepatitis delta. New data
will be presented from the cohorts evaluating the de novo
combination of tobevibart and elebsiran dosed every four weeks and
tobevibart monotherapy every two weeks. Additional 24-week data
from these cohorts are expected in the fourth quarter of 2024.
About Tobevibart (VIR-3434)
Tobevibart is an investigational subcutaneously administered
antibody designed to block entry of hepatitis B and hepatitis delta
viruses into hepatocytes and to reduce the level of virions and
subviral particles in the blood. Tobevibart, which incorporates
Xencor’s Xtend™ and other Fc technologies, has been engineered to
potentially function as a T cell vaccine against hepatitis B virus
and hepatitis delta virus, as well as to have an extended
half-life. Tobevibart was identified using Vir’s proprietary
monoclonal antibody discovery platform.
About Elebsiran (VIR-2218)
Elebsiran is an investigational subcutaneously administered
hepatitis B virus-targeting small interfering ribonucleic acid
(siRNA) that Vir believes has the potential to stimulate an
effective immune response and have direct antiviral activity
against hepatitis B virus and hepatitis delta virus. It is the
first siRNA in the clinic to include Enhanced Stabilization
Chemistry Plus (ESC+) technology to enhance stability and minimize
off-target activity, which potentially could result in an increased
therapeutic index. Elebsiran is the first asset in the Company’s
collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical
trials.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including viral-associated diseases. Vir has assembled two
technology platforms that are designed to modulate the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses, and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding Vir’s
strategy and plans, the potential clinical effects of tobevibart
and elebsiran, the potential benefits, safety and efficacy of
tobevibart and elebsiran, the timing, nature and significance of
data from Vir’s multiple ongoing trials evaluating tobevibart and
elebsiran, Vir’s plans and expectations for its CHD and CHB
programs, and risks and uncertainties associated with drug
development and commercialization. Many factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data or results observed
during clinical trials or in data readouts; the occurrence of
adverse safety events; risks of unexpected costs, delays or other
unexpected hurdles; difficulties in collaborating with other
companies; successful development and/or commercialization of
alternative product candidates by Vir’s competitors; changes in
expected or existing competition; delays in or disruptions to Vir’s
business or clinical trials due to geopolitical changes or other
external factors; and unexpected litigation or other disputes. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516732892/en/
Media Carly Scaduto Senior Director, External
Communications cscaduto@vir.bio +1 314-368-5189
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio +1 978-973-9986
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 5 2024 まで 6 2024
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 6 2023 まで 6 2024